SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports [Yahoo! Finance]
SCYNEXIS, Inc. (SCYX)
Last scynexis, inc. earnings: 11/12 08:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.scynexis.com/investor-relations
Company Research
Source: Yahoo! Finance
company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it will receive a $10 million development milestone payment under its exclusive license agreement with GSK for ibrexafungerp. The milestone payment is triggered by the delivery of final clinical study reports for the completed FURI, CARES, and NATURE clinical studies. "We are pleased to have completed these important studies in refractory invasive fungal infections, for which there remains an urgent need to deliver new solutions and combat growing resistance," said David Angulo, M.D., President and Chief Executive Officer of SCYNEXIS. "Work continues to reestablish the supply chain of ibrexafungerp, and we look forward to restarting the Phase 3 MARIO study in invasive candidiasis. Our balance sheet remains robust, and our cash runway exceeds two years as we advance our next generation fungerp, SCY-247, into the clinic later this year." Results from
Show less
Read more
Impact Snapshot
Event Time:
SCYX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SCYX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SCYX alerts
High impacting SCYNEXIS, Inc. news events
Weekly update
A roundup of the hottest topics
SCYX
News
- SCYNEXIS, Inc. (NASDAQ: SCYX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- SCYNEXIS Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]Yahoo! Finance
- SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswire
- SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual SummitGlobeNewswire
SCYX
Earnings
- 11/6/24 - Beat
SCYX
Sec Filings
- 11/14/24 - Form SC
- 11/6/24 - Form 8-K
- 11/6/24 - Form 424B5
- SCYX's page on the SEC website